## Mark Crowther

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9568420/mark-crowther-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179	19,924	54	141
papers	citations	h-index	g-index
193	23,007 ext. citations	7.4	6.6
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
179	Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review <i>Thrombosis Research</i> , <b>2022</b> , 213, 16-26	8.2	O
178	Iron Chelation Therapy in Low- to Intermediate- Risk Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2021</b> , 138, 4661-4661	2.2	
177	Thrombotic Events in COVID-19 Patients Undergoing Convalescent Plasma Therapy: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 3221-3221	2.2	
176	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 1	5.1	
175	Double Blind Pilot Randomized Trial Comparing Extended Anticoagulation to Placebo Following Major Lung Resection for Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2021</b> , 33, 1123-1134	1.7	1
174	Iron supplementation following bariatric surgery: A systematic review of current strategies. <i>Obesity Reviews</i> , <b>2021</b> , 22, e13268	10.6	2
173	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , <b>2021</b> , 52, 2096-2105	6.7	5
172	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , <b>2021</b> , 126, 163-171	5.4	9
171	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , <b>2021</b> , 126, 172	- <del>18</del> 0	3
170	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 157, 103125	7	1
169	Canadian stroke best practice recommendations: , 7th Edition Update 2020. <i>International Journal of Stroke</i> , <b>2021</b> , 16, 321-341	6.3	18
168	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. <i>Critical Care Medicine</i> , <b>2021</b> , 49, e219-e234	1.4	119
167	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1097-1106	7	5
166	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs - A Systematic Review and Meta-analysis. <i>TH Open</i> , <b>2021</b> , 5, e438-e448	2.7	2
165	Reduced-dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: A systematic review and meta-analysis-Response to Commentary. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2359-2360	15.4	O
164	Equity and Game-Theory Strategies to Promote Gender Diversity and Inclusion in an Academic Health Science Centre <i>CJC Open</i> , <b>2021</b> , 3, S53-S61	2	1
163	A systematic review of the association between anti-E2 glycoprotein I antibodies and APS manifestations. <i>Blood Advances</i> , <b>2021</b> , 5, 3931-3936	7.8	O

## (2020-2021)

162	Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial. <i>Academic Emergency Medicine</i> , <b>2021</b> ,	3.4	4	
161	Iron chelation therapy in patients with low- to intermediate-risk myelodysplastic syndrome: A systematic review and meta-analysis <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	O	
160	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus <i>Current Oncology</i> , <b>2021</b> , 28, 5434-5451	2.8	4	
159	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. <i>BMC Medical Research Methodology</i> , <b>2020</b> , 20, 113	4.7	12	
158	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2274-2286	15.4	8	
157	The value of bleeding scores in the assessment of patients presenting with bleeding of unknown cause: Complex algorithms with little predictive value. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 26-27	3.9	1	
156	Evaluating the quality of systematic reviews and meta-analyses published on direct oral anticoagulants in the past 5 years. <i>BMJ Evidence-Based Medicine</i> , <b>2020</b> ,	2.7	1	
155	Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). <i>Blood Advances</i> , <b>2020</b> , 4, 2460-2467	7.8	3	
154	Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2308-2317	15.4	2	
153	Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. <i>Hematology</i> , <b>2020</b> , 25, 112-117	2.2	6	
152	Fibrin and Thrombin Sealants in Vascular and Cardiac Surgery: A Systematic Review and Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>2020</b> , 60, 469-478	2.3	6	
151	GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 122, 129-141	5.7	81	
150	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. <i>Blood</i> , <b>2020</b> , 135, 239-251	2.2	72	
149	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1940-1951	15.4	24	
148	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology,the</i> , <b>2020</b> , 7, e18-e27	14.6	74	
147	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 132-140	7	17	
146	Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. <i>Thrombosis Research</i> , <b>2020</b> , 194, 240-245	8.2	14	
145	GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 122, 142-152	5.7	80	

144	Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. <i>Blood Advances</i> , <b>2020</b> , 4, 5373-5377	7.8	29
143	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2126-2137	15.4	30
142	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology,the</i> , <b>2020</b> , 7, e746-e755	14.6	8
141	A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. <i>Blood Advances</i> , <b>2020</b> , 4, 728-739	7.8	11
140	Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 1993-2002	27.4	134
139	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 697-709	7.1	123
138	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1326-1335	59.2	431
137	The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1956-1965	15.4	15
136	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1966-1976	27.4	52
135	Frequency of arterial thromboembolism in populations with malignancies: A systematic review. <i>Thrombosis Research</i> , <b>2019</b> , 184, 16-23	8.2	11
134	Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial. <i>Blood</i> , <b>2019</b> , 134, 3685-3685	2.2	5
133	Case Report: Two Cases of Strongyloidiasis Presenting with Thrombotic Events. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2019</b> , 101, 418-421	3.2	2
132	Evaluating the Quality of Systematic Reviews & Meta-Analyses Published on Direct Oral Anticoagulants in the Past 5 Years. <i>Blood</i> , <b>2019</b> , 134, 5802-5802	2.2	
131	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. <i>Blood</i> , <b>2019</b> , 134, 711-711	2.2	O
130	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2019</b> , 184, 58-61	8.2	13
129	Severe coagulopathy after a massasauga rattlesnake bite. <i>Cmaj</i> , <b>2018</b> , 190, E191-E194	3.5	2
128	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 699-707	59.2	189
127	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 842-851	7	114

#### (2017-2018)

126	September 22 and 23, 2017, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 578-587	5.1	
125	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , <b>2018</b> , 8, e021900	3	12
124	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , <b>2018</b> , 101, 362-367	3.8	4
123	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 2518-2518	2.2	
122	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , <b>2018</b> , 162, 104-109	8.2	17
121	The risk of venous thromboembolism in patients with clinically overt gastrointestinal bleeding. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E42-E45	7.1	O
120	Andexanet alfa for the treatment of hemorrhage. Expert Review of Hematology, 2018, 11, 847-855	2.8	2
119	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. <i>Blood Advances</i> , <b>2018</b> , 2, 3155-3162	7.8	24
118	Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. <i>Vox Sanguinis</i> , <b>2017</b> , 112, 268-278	3.1	35
117	Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 1322-1333	15.4	36
116	Specific antidotes for bleeding associated with direct oral anticoagulants. <i>BMJ, The</i> , <b>2017</b> , 357, j2216	5.9	15
115	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 21180-21192	5.4	11
114	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology,the</i> , <b>2017</b> , 4, e544-e552	14.6	27
113	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. <i>CMAJ Open</i> , <b>2017</b> , 5, E594-E603	2.5	6
112	Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , <b>2017</b> , 2017, 926	1331	13
111	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , <b>2017</b> , 1, 1827-1838	7.8	35
110	Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 80-87	2.6	18
109	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2017</b> , 160, 97-104	8.2	11

108	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. <i>Chest</i> , <b>2017</b> , 151, 127-138	5.3	185
107	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome <b>2017</b> , 223-233		4
106	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1131-41	59.2	580
105	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 879-890	7	95
104	A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. <i>BMC Hematology</i> , <b>2016</b> , 16, 17	2.5	3
103	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 32-67	5.1	167
102	Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 142-9	27.4	401
101	Postdischarge venous thromboembolic complications following pulmonary oncologic resection: An underdetected problem. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2016</b> , 151, 992-9	1.5	20
100	Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of Crcl . <i>Blood</i> , <b>2016</b> , 128, 90-90	2.2	4
99	Modified Early Warning Score (MEWS) Identifies Critical Illness among Ward Patients in a Resource Restricted Setting in Kampala, Uganda: A Prospective Observational Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e01514	ŀ08 <sup>7</sup>	48
98	Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2016</b> , 128, 88-88	2.2	
97	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 480-5	7	4
96	Rapid quantitative D-dimer to exclude pulmonary embolism: a prospective cohort management study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 504-9	15.4	20
95	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <i>European Journal of Epidemiology</i> , <b>2016</b> , 31, 541-61	12.1	15
94	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , <b>2016</b> , 6, e010569	3	14
93	Andexanet Alfa for Factor Xa Inhibitor Reversal. New England Journal of Medicine, 2016, 375, 2499-500	59.2	19
92	Thrombosis and anticoagulation in the setting of renal or liver disease. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 188-195	3.1	25
91	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 671-81	5.3	5

## (2013-2016)

90	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. <i>American Journal of Medicine</i> , <b>2016</b> , 129, e247-8	2.4	11
89	Antidotes for novel oral anticoagulants: current status and future potential. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 1736-45	9.4	105
88	Venous thromboembolism prophylaxis in critically ill patients. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2015</b> , 41, 68-74	5.3	36
87	Aspirin in secondary prevention of recurrent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 39, 392-4	5.1	5
86	Integrating electronic health records in the delivery of optimized anticoagulation therapy. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 125-6	2.9	
85	Systematic review of anticoagulant treatment of catheter-related thrombosis. <i>Thrombosis Research</i> , <b>2015</b> , 136, 1103-9	8.2	17
84	The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. <i>Blood Transfusion</i> , <b>2015</b> , 13, 559-68	3.6	49
83	Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1128-39	15.1	357
82	Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. <i>Journal of Critical Care</i> , <b>2014</b> , 29, 470.e7-15	4	34
81	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , <b>2014</b> , 120, 564-78	4.3	509
80	Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit. <i>Critical Care</i> , <b>2014</b> , 18, R82	10.8	15
79	The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. <i>Blood</i> , <b>2014</b> , 124, 2450-8	2.2	237
78	The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. <i>Allergy and Asthma Proceedings</i> , <b>2014</b> , 35, 444-53	2.6	25
77	Portal vein thrombosis: a clinician-oriented and practical review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2014</b> , 20, 498-506	3.3	21
76	Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 841	7	5
75	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. <i>Blood</i> , <b>2014</b> , 124, 4269-4269	2.2	68
74	Reversal of target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 195-2	203.1	31
73	Antithrombotic Agents <b>2013</b> , 477-495		2

Thrombosis 2013, 67-77 72 7 Phase 4 research: what happens when the rubber meets the road?. Hematology American Society of 3.1 10 Hematology Education Program, 2013, 2013, 15-8 Indications, complications, and management of inferior vena cava filters: the experience in 952 168 11.5 patients at an academic hospital with a level I trauma center. JAMA Internal Medicine, 2013, 173, 513-7 Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. 69 36 Thrombosis and Haemostasis, 2013, 110, 1172-9 Response to Dr Junqueira. Chest, 2013, 143, 1191 68 5.3 1 Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, 67 5.3 122 and outcomes. Chest, 2013, 144, 1207-1215 66 Heparin-induced thrombocytopenia in medical surgical critical illness. Chest, 2013, 144, 848-858 5.3 45 Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis 65 131 after total hip arthroplasty: a randomized trial. Annals of Internal Medicine, 2013, 158, 800-6 A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with 64 2.2 92 immune thrombocytopenia. Blood, 2012, 119, 1356-62 Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, 63 but not in that induced by dabigatran etexilate. Journal of Thrombosis and Haemostasis, 2012, 10, 1830- $40^{5.4}$ 78 Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 62 5.3 2575 2012, 141, e419S-e496S Newer anticoagulants in critically ill patients. Critical Care Clinics, 2012, 28, 427-51, vii 61 4.5 4 Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 60 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **2012**, 141, e445 888 1112 Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical 687 59 5.3 Practice Guidelines. Chest, 2012, 141, e495S-e530S Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American 58 5.3 1225 College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141, 7S-47S Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 57 109 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141, 48S-\$2S Methodology for the development of antithrombotic therapy and prevention of thrombosis quidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of 56 5.3 177 Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141, 53S-70S Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice 920 5.3 Guidelines. Chest, 2012, 141, e152S-e184S

## (2010-2012)

54	Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. <i>American Journal of Hematology</i> , <b>2012</b> , 87 Suppl 1, S141-5	7.1	280
53	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 143-63	5.1	
52	Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit. <i>Evidence-Based Medicine</i> , <b>2012</b> , 17, 154-5		
51	Approaches to diagnosing and managing anticoagulant-related bleeding. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 702-10	5.3	12
50	Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. <i>Circulation</i> , <b>2012</b> , 126, 2381-91	16.7	307
49	Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e351S-e418S	5.3	449
48	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 429-38	7	273
47	Treatment of warfarin-associated coagulopathy with vitamin K. <i>Expert Review of Hematology</i> , <b>2011</b> , 4, 657-65; quiz 666-7	2.8	33
46	Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism. <i>British Journal of Haematology</i> , <b>2011</b> , 155, 511-3	4.5	2
45	Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 249-58	5.1	30
44	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, SB Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 32, 242-66	5.1	2
43	Dalteparin versus unfractionated heparin in critically ill patients. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1305-14	59.2	306
42	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 118-21	7	29
41	Hematology/Oncology Clinics of North America. Hypercoagulable states and new anticoagulants. Preface. <i>Hematology/Oncology Clinics of North America</i> , <b>2010</b> , 24, xiii-xiv	3.1	1
40	Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations. <i>Hematology/Oncology Clinics of North America</i> , <b>2010</b> , 24, 669-76, vii	3.1	3
39	The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. <i>Contemporary Clinical Trials</i> , <b>2010</b> , 31, 131-3	2.3	21
38	Intensity of warfarin coagulation in the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 64-9	4.9	11
37	Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1926-32	15.4	28

36	Hot topics in parenteral nutrition. A review of the use of glutamine supplementation in the nutritional support of patients undergoing bone-marrow transplantation and traditional cancer therapy. <i>Proceedings of the Nutrition Society</i> , <b>2009</b> , 68, 269-73	2.9	7
35	Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review. <i>Transfusion Medicine Reviews</i> , <b>2009</b> , 23, 155-9	7.4	33
34	Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. <i>Journal of Critical Care</i> , <b>2009</b> , 24, 197-205	4	35
33	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 584-8	7.1	51
32	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 579-83	7.1	12
31	Definition of major bleeding used by US anticoagulation clinics. <i>Thrombosis Research</i> , <b>2009</b> , 124, 239-40	8.2	3
30	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. <i>Thrombosis Research</i> , <b>2009</b> , 123, 687-96	8.2	244
29	Predicting deep venous thrombosis in pregnancy: out in "LEFt" field?. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 85-92	8	85
28	2009 evidence-based clinical practice guidelines for diagnosing a first episode of lower extremities deep vein thrombosis in ambulatory outpatients <b>2009</b> , 119, 541-9		1
27	Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 705-6	1.5	53
26	Preventing and managing bleeding complications in anticoagulated patients: a case based approach. <i>Thrombosis Research</i> , <b>2008</b> , 123 Suppl 1, S42-5	8.2	
25	Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. <i>Critical Care</i> , <b>2008</b> , 12, R32	10.8	58
24	Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 1805-12		110
23	Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. <i>Cmaj</i> , <b>2008</b> , 179, 417-26	3.5	376
22	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 160S-198S	5.3	1648
21	The clinical consequence of subtherapeutic anticoagulation: the low INR study (LINeRS). <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 25, 127-128	5.1	
20	Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 25, 96-9	6 <sup>5.1</sup>	1
19	Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 117-24		140

#### (2000-2007)

18	A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 165-70	8	94
17	Treatment of Antiphospholipid Antibody Syndrome <b>R</b> eply. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 42	27.4	2
16	The risk of hemorrhage among patients with warfarin-associated coagulopathy. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 804-8	15.1	65
15	The metabolic syndrome and the risk of venous thrombosis: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 1914-8	15.4	127
14	The Management of Anticoagulated Patients Requiring Dental Extraction: A Cross-Sectional Survey of Oral Surgeons and Hematologists <i>Blood</i> , <b>2006</b> , 108, 629-629	2.2	
13	Use of Therapeutic Dose Low Molecular Weight Heparin in Patients with Renal Insufficiency: Analysis of Anti-Xa Levels and Creatinine Clearance <i>Blood</i> , <b>2006</b> , 108, 884-884	2.2	
12	A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 732-3	15.1	29
11	Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. <i>Critical Care Medicine</i> , <b>2005</b> , 33, 1565-71	1.4	895
10	Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. <i>Chest</i> , <b>2005</b> , 127, 2049-56	5.3	181
9	Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. <i>British Journal of Haematology</i> , <b>2005</b> , 129, 803-10	4.5	76
8	Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. <i>Intensive Care Medicine</i> , <b>2005</b> , 31, 48-55	14.5	54
7	Systematic overview of warfarin and its drug and food interactions. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 1095-106		767
6	The Safety of Co-Administered Low-Molecular-Weight Heparin and Continuous Epidural Analgesia after Major Orthopedic Surgery: Assessment of a Standardized Management Protocol <i>Blood</i> , <b>2004</b> , 104, 704-704	2.2	3
5	New anticoagulants: an update. Clinical Advances in Hematology and Oncology, 2004, 2, 743-9	0.6	
4	A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. <i>Annals of Internal Medicine</i> , <b>2003</b> , 138, 787-94	8	90
3	Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. <i>Annals of Internal Medicine</i> , <b>2001</b> , 135, 108-11	8	128
2	Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study. <i>Journal of Critical Care</i> , <b>2001</b> , 16, 161-6	4	25
1	Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. <i>Journal of Critical Care</i> , <b>2000</b> , 15, 127-32	4	94